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ABSTRACT
Human artificial chromosome (HAC)-based vectors
represent an alternative technology for gene delivery
and expression with a potential to overcome the
problems caused by the use of viral-based vectors.
The recently developed alphoidtetO-HAC has an ad-
vantage over other HAC vectors because it can be
easily eliminated from cells by inactivation of the
HAC kinetochore via binding of tTS chromatin modi-
fiers to its centromeric tetO sequences. This
provides unique control for phenotypes induced by
genes loaded into the alphoidtetO-HAC. However, in-
activation of the HAC kinetochore requires transfec-
tion of cells by a retrovirus vector, a step that is
potentially mutagenic. Here, we describe an
approach to re-engineering the alphoidtetO-HAC
that allows verification of phenotypic changes
attributed to expression of genes from the HAC
without a transfection step. In the new HAC vector,
a tTS-EYFP cassette is inserted into a gene-loading
site along with a gene of interest. Expression of the
tTS generates a self-regulating fluctuating hetero-
chromatin on the alphoidtetO-HAC that induces fast
silencing of the genes on the HAC without signifi-
cant effects on HAC segregation. This silencing of
the HAC-encoded genes can be readily recovered
by adding doxycycline. The newly modified
alphoidtetO-HAC-based system has multiple applica-
tions in gene function studies.
INTRODUCTION
Human artiﬁcial chromosomes or HAC-based vectors rep-
resent a novel system for gene delivery and expression that
has several advantages over previous gene and cell therapy
strategies (1–7). All HACs by deﬁnition contain a func-
tional centromere and, therefore, represent a non-essential
47th chromosome that replicates and segregates like a
normal chromosome in human cells, thereby avoiding in-
tegration into the host genome. HAC vectors have essen-
tially unlimited cloning capacity; therefore, they are able to
carry genes or genomic fragments up to several mega base
pairs. Thus, HAC-based gene delivery vectors may provide
long-term expression of complete genetic loci, while
reducing the risk of an immune response and transgene
silencing characteristic of viral-based vectors (8–12).
Moreover, the presence of internal promoters, splicing
sites and polyadenylation [poly(A)] sites allows tissue-
speciﬁc expression of the therapeutic genes, making
HACs suitable for gene delivery to different types of
target cells. Several laboratories succeeded in complemen-
tation of gene deﬁciency in human recipient cell lines and
in creation of transgenic mice using HAC vectors contain-
ing genomic copies of the genes with all their regulatory
elements, demonstrating their potential as therapeutic gene
expression vectors (13–24). A particularly impressive
example is stem-cell–mediated gene replacement therapy
in dystrophic mice using a HAC expressing the human
2.4-Mb dystrophin (DYS) gene (25,26). Tedesco et al.
(27,28) reported transfer of this HAC carrying the entire
human dystrophin genetic locus into blood vessel-
associated stem cells (mesoangioblasts). Transfer of these
genetically corrected cells to the mdx mouse resulted in the
amelioration of dystrophic phenotypes in the mouse model
of Duchenne muscular dystrophy. This example of HAC-
mediated gene transfer shows efﬁcacy in a pre-clinical
model of Duchenne muscular dystrophy and offers the po-
tential for future clinical translation.
HACs are engineered by ‘top-down’ or ‘bottom-up’
(de novo formation) approaches (1–7). The top-down
approach is based on a telomere-associated human
chromosome truncation technique. The bottom-up
approach includes transfection of human cells with
either natural high-order repeat or synthetic a-satellite
(alphoid) DNA with a size bigger than 30 kb. In this
case, HAC formation is accompanied by multimerization
of the input DNA in the cell up to 1–5Mb.
Recently, a new generation de novo HAC, the
alphoidtetO-HAC, was engineered using a 40-kb synthetic
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alphoid DNA array (29). This array contains 42-bp tetra-
cycline operator (tetO) sequences incorporated into every
second alphoid DNA monomer. After ampliﬁcation of the
input DNA (40 kb) in human HT1080 cells and HAC for-
mation, the resulting alphoidtetO-HAC contains <6000
copies of the tetO sequence in the 1.1 mega-base size
alphoid DNA array. Because tetO sequences are bound
with very high afﬁnity and speciﬁcity by the tet repressor
(tetR), the tetO sequences in the HAC can be targeted
efﬁciently in vivo with tetR fusion proteins. The power
of this system is that it allows the speciﬁc manipulation
of the chromatin composition of a HAC kinetochore
in vivo, whereas it leaves all kinetochores of the natural
chromosomes unperturbed. Targeting of chromatin-mod-
ifying proteins into the HAC kinetochore demonstrated
that a balance between open and condensed chromatin
is critical for kinetochore function (29–34). The frequency
of HAC loss was very high when repressive chromatin was
induced in the HAC via the tTS (tet-repressor transcrip-
tional silencer) (which contains the KRAB-AB domain of
the SDkid-1 protein). tTS binding caused the loss of CENP-
A, CENP-B, CENP-C and H3K4me2 from the HAC kin-
etochore accompanied by an accumulation of histone
H3K9me3 on the alphoid DNA array. As a consequence,
the functional HAC kinetochore was inactivated (29–34).
This alphoidtetO-HAC elimination was highly efﬁcient
using either retrovirus or plasmid-induced expression to
provide a high level of chromatin modiﬁers as tetR
fusion proteins (Figure 1a).
The alphoidtetO-HAC with a regulated kinetochore rep-
resents a novel system for gene function analysis and po-
tentially for gene therapy because it provides a unique
possibility to compare the phenotypes of target human
cells with and without a functional copy of a gene
inserted into the HAC. Such a rigorous control is
required for proper interpretation of gene complementa-
tion studies. To adopt the existing alphoidtetO-HAC for
gene delivery and expression studies, the HAC containing
a loxP gene-loading site was transferred to Chinese
hamster ovary (CHO) cells via micro-cell–mediated
chromosome transfer (MMCT) (35). In those cells, a
gene of interest can be easily inserted into the loxP site
of the HAC by Cre-mediated recombination. In addition,
the HAC can be transferred from these cells into different
recipient cells via MMCT. Because physical characteriza-
tion of the alphoidtetO-HAC was carried out (36), this
HAC is an excellent candidate for gene function studies.
Recently, we reported the capacity of the alphoidtetO-HAC
to deliver genomic copies of two human genes, VHL
(25 kb) and NBS1 (60 kb), and complement genetic
deﬁciencies in patient-derived cell lines (37). Functional
expression of pVHL and pNBS1 in recipient cells was
proven by a set of speciﬁc tests based on the known func-
tions of those proteins. Corresponding controls were con-
ducted following elimination of the HAC from the cells by
transfection with a retrovirus vector carrying a tTS chro-
matin silencer to inactivate HAC centrochromatin.
It is well known that transfection by both plasmid and
retroviral vectors is potentially mutagenic. In this report,
we describe re-engineering of an alphoidtetO-HAC vector
to allow veriﬁcation of phenotypic changes attributed to
the expression of genes from the HAC without the neces-
sity of viral transfection of the HAC-bearing cells. As a
proof of principle, a gene of interest was inserted into the
HAC along with a tTS-EYFP expression cassette. Such a
conﬁguration of effector (tTS) and target (tetO) appar-
ently generates a self-regulating ﬂuctuating repressive het-
erochromatin-like system that can be used to induce
silencing of genes loaded into the HAC without a signiﬁ-
cant effect on the HAC segregation. This feature of the
alphoidtetO-HAC carrying tTS is consistent with its poten-
tial broad use in gene function study experiments.
MATERIALS AND METHODS
Cell lines and media
The hypoxanthine phosphoribosyltransferase (HPRT)-de-
ﬁcient HT1080 cell line was obtained from Dr Zoia Larin
Monaco (Wellcome Trust Centre for Human Genetics,
University of Oxford, Oxford, UK). The cells were cul-
tured in Dulbecco’s modiﬁed Eagle’s medium (Invitrogen)
supplemented with 10% (v/v) tet system-approved fetal
bovine serum (Clontech Laboratories, Inc.) at 37C in
5% CO2. HPRT-deﬁcient Chinese hamster ovary (CHO)
cells (JCRB0218) carrying the alphoidtetO-HAC were
maintained in Ham’s F-12 nutrient mixture (Invitrogen)
plus 10% FBS with 8 mg/ml of blasticidin (BS)
(Invitrogen). After loading of the transgene cassettes
into the alphoidtetO-HAC, the HT1080 and CHO cells
were cultured in 1 HAT medium (Invitrogen). Concen-
tration of doxycycline in the medium was 1 mg/ml.
Micro-cell–mediated chromosome transfer
The alphoidtetO-HAC containing a single loxP gene-
loading site was transferred from CHO cells to
HPRT-deﬁcient HT1080 cells using a standard MMCT
protocol (35,38). The whole MMCT procedure takes 4
days (the growth of cells in the presence of colcemid for
3 days and the MMCT procedure itself 1 day). BS was
used to select colonies with the HAC. Selection of BSR
clones usually takes 2–3 weeks. Typically, 3–10 BSR
colonies were obtained in one MMCT experiment. The
BSR colonies were analyzed by ﬂuorescence in situ hy-
bridization (FISH) for the presence of the autonomous
form of the HAC. The potential co-transfer of CHO
chromosomes was excluded using a sensitive PCR test
for rodent-speciﬁc SINE elements (Supplementary
Table S1).
FISH analysis
FISH analysis was performed as previously described
(29,37). HAC-containing cells were cultured in medium
with 10 mg/ml of colcemid (Invitrogen) for 3 h at 37C.
Metaphase cells were trypsinized and collected by centri-
fugation for 5min at 483g, treated in hypotonic solution
50mM KCl for 20min at 37C and washed in metha-
nol:acetic acid (3:1) solution three times. Cells were
diluted to the appropriate density with ﬁxative solution,
spread onto pre-cleaned slides (Fisher Scientiﬁc) above
steam (boiling water) and allowed to age 2 days at room
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temperature. Metaphase chromosomes on the slide were
denatured by 70% formamide/2 SSC for 2min at 72C.
Samples were dehydrated through a 70, 90 and 100%
ethanol series for 4min each and left to air-dry. Orange
552 dUTP (5-TAMRA-dUTP) (Abbott Molecular)
labeled probes were denatured in hybridization solution
at 78C for 10min and left at 37C for 30min. The hy-
bridization mix probe was applied to the sample and
incubated at 37C overnight. Slides were washed with
0.4 SSC, 0.3% Tween 20 for 2min at 72C, brieﬂy
rinsed with 2 SSC, 0.1% Tween 20 (5 s to 1min) and
air dried in darkness. The samples were counterstained
with Vectashield mounting medium with DAPI (Vector
Laboratories). Slides were analyzed by ﬂuorescence
microscopy. Images were captured using a DeltaVision
microscopy imaging system in the CRC, LRBGE Fluore-
scence Imaging Facility (NIH) and analyzed using image J
software (NIH).
The probe used for FISH analysis
The probe used for FISH was BAC32-2mer(tetO) DNA
containing 40 kb of alphoid-tetO array cloned into a BAC
vector as described previously (29). BAC DNA was
labeled using a nick-translation kit with Orange 552
dUTP (5-TAMRA-dUTP) (Abbott Molecular).
Analysis of HAC mitotic stability by FISH
Fluorescence images of human and hamster cells carrying
the HAC with tTS-containing cassettes were analyzed.
Cells were processed for FISH using a BAC-based probe
after 7, 20 and 36 days of culturing without HAT selection
in the presence or absence of doxycycline. Metaphase
spreads were screened for the presence or absence of the
HAC. At least 60 metaphases were screened for each
clone. The loss rate (R) was calculated using the formula
N1=N0 (1R)n, where N0=percentage of metaphase
(a)
(b)
Expression of tTS from viral vector
(c)
centrochromatin
tTS protein
spreading of
heterochromatin
HAC loss
HAC
loxP Disruption of centrochromatin
HAC loss
tTS
spreading of
heterochromatin
Expression of tTS
tTS self inactivation
localized heterochromatization Gene
silencing
Figure 1. A scheme illustrating epigenetic changes in the alphoidtetO-HAC caused by tTS expression. (a) The condition when tTS is highly expressed
from a retroviral vector in trans. Multiple tTS molecules bind to a great fraction of tetO sequences in the HAC and as previously shown lead to the
formation of heterochromatin, spreading of which disrupts centrochromatin. As a result, the HAC kinetochore is inactivated, and the HAC is lost.
(b and c) Conditions where a single copy of tTS is integrated into the HAC. The main difference of this system compared with viral expression is that
fewer targets (tetO sequences) are bound by the effectors (tTS protein), as less protein is synthesized. Two scenarios are possible. (b) Despite the
limited number of tTS molecules binding to tetO sequences in the HAC, active spreading of heterochromation induced by tTS results in the disruption
of centrochromatin domains. (c) Binding of the limited number of tTS molecules to alphoid DNA array induces formation of the local chromatin
domains that do not compromise activity of the HAC kinetochore but completely blocks transcription of the sequences within these domains. One of
these domains is located near the gene-loading site leading to self-silencing of the tTS gene and transgenes nearby.
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spreads with alphoidtetO-HAC in cells cultured under se-
lection, N1=percentage of alphoid
tetO-HAC-containing
metaphase spreads after n days of culture in the absence
of selection (20).
Construction of the tTS-containing cassettes used for
loading into the HAC
The construction of the control X3.1-I-EGFP-I cassette
(also referred as 264-EGFP) (construct #1) was described
previously (35). The transgene cassettes tetR-IRES-
DsRed2 (construct #2), tTS-IRES-DsRed2 (construct
#3) and tTS-EYFP (construct #4) were assembled as
follows. The X3.1-I-EGFP-I DNA was digested with
BsrGI/SpeI. The 7241-bp fragment without the EYFP
transgene was extracted from the gel and ligated with a
synthetic polylinker (Supplementary Table S1) (Integrated
DNA Technologies), producing the intermediate plasmid
265. The CAG promoter was isolated as a 1734-bp
fragment by digestion of X3.1-I-EGFP-I using KpnI/
EcoRI. This fragment was cloned into the pBluescript
KS vector (Fermentas). Next, the CAG promoter-contain-
ing fragment was digested by SpeI and re-cloned into a
single SpeI site of plasmid 265, producing the plasmid 266.
This plasmid was used as a basic construct for further
insertion of different cassettes. The tTS-EYFP cassette
was ampliﬁed from the pFB-tTS-EYFP vector (29) using
a pair of speciﬁc primers PacI-rtTS-GFP-F/AvrII-rtTS-
GFP-R (Supplementary Table S1) and inserted into
AvrII/PacI sites of the plasmid 266, producing the trans-
gene construct #4 (tTS-EYFP). To construct the transgene
cassette tTS-IRES-DsRed2 (construct #3), the tTS
fragment of 849 bp was ampliﬁed from pFB-tTS-EYFP
plasmid (29) with a pair of primers PacI-rtTS-IRES-
Red-F/XmaI-rtTS-R (Supplementary Table S1). The
IRES/DsRed2 fragment of 1261 bp was ampliﬁed from
the 264-CAG-OKS-EF1-tTKRAB-DsRed-pA plasmid
(kindly provided by Dr Tomilin, Institute of Cytology,
RAS, Russia) with a pair of primers XmaI-IRES-Red-F/
NheI-rtTS-IRES-Red-R (Supplementary Table S1). The
fragments were digested by PacI/XmaI and XmaI/NheI,
correspondingly, and cloned into the basic plasmid 266
digested by PacI/NheI by one ligation step, producing
the transgene cassette tetR-tTS-IRES-DsRed2 (construct
#3). To construct the transgene cassette tetR-IRES-
DsRed2 (construct #2), the tetR-NLC fragment of
654 bp was ampliﬁed from the plasmid pTetR-TS
(Clontech) with a pair of primers PacI-rtTS-IRES-Red-
F/XmaI-tetR-NLS-R (Supplementary Table S1) and
then digested by PacI/XmaI. The fragments tetR-NLS
and IRES/DsRed2 were cloned into the basic plasmid
266 digested by PacI/NheI by one ligation step, producing
the transgene cassette tetR-IRES-DsRed2 (construct #2).
Detailed physical maps of the cassettes are shown in
Supplementary Figure S1.
Loading of the transgene cassettes into the loxP site of
the alphoidtetO-HAC
A total of 1–3 mg of transgene construct DNA and 1 mg of
the Cre expression pCpG-iCre vector DNA were co-trans-
formed into HPRT-deﬁcient human HT1080 cells
containing the alphoidtetO-HAC by lipofection with
X-tremeGENE 9 DNA transfection reagent (Roche) or
Lipofectamine 2000 (Invitrogen). HPRT-positive
colonies were selected after 2–3 weeks growth in HAT
medium. For each transgene cassette, from ﬁve to seven
clones were selected. Correct loading of the transgene cas-
settes into the HAC was conﬁrmed by genomic PCR with
a speciﬁc pair of primers that diagnose reconstitution of
the HPRT gene (Supplementary Table S1). Conditions of
a transgene loading into the alphoidtetO-HAC propagated
in CHO hamster cells were described previously (35,37).
RT–PCR analysis
Expression of the Hygro, HS-tk, HPRT, BRCA1 and
EGFP genes was checked by RT–PCR. Pairs of speciﬁc
primers were designed to amplify each gene as 265-, 267-,
449-, 893- and 483-bp fragments, respectively (Supple-
mentary Table S1). cDNA was made from 1 mg of total
RNA isolated from dox+and dox cultured HT1080 cells
using the RevertAidTM First Strand cDNA Synthesis Kit
(Fermentas) and priming with oligo dT as recommended
by the kit supplier. RT–PCR reactions were performed
with 1 ml of cDNA in a 50-ml volume. Standard reaction
conditions were 95C for 30 s, 60C for 30 s, 72C for
45 s 35 cycles. The PCR products were sequenced on a
PE-Applied Biosystem 3100 Automated Capillary DNA
Sequencer.
Trichostatin A and suberoylanilide hydroxamic acid
treatment
Aliquots of 2.4 106 HT1080 cells carrying the
alphoidtetO-HAC with the silenced tTS-EYFP were
incubated in 2ml of non-selective medium containing
either 100 ng/ml of Trichostatin A (TSA) (Wako) or in
10mM of suberoylanilide hydroxamic acid (SAHA)
(Vorinostat) for 24 h in the presence of doxycycline.
Then cell samples were collected and analyzed by FACS.
FACS analysis
FACS analysis of EYFP and DsRed2 expression was per-
formed on a FACSCalibur instrument (BD Biosciences)
controlled using CellQuest acquisition software and
analyzed statistically with FlowJo software (39,40). A
minimum of 4 104 cells were analyzed for each cell
sample.
Southern-blot hybridization analysis
Southern-blot hybridization was performed with a 32P-
labeled probe. Genomic DNA was prepared in agarose
plugs and restriction digested by PmeI or SpeI. The
digested DNA was CHEF separated, and blot-hybridized
with a 276-bp probe speciﬁc to a tetO-containing alphoid
sequence (36). The probe sequence was PCR ampliﬁed
from BAC32-2-mer/tetO (29) using the primers listed in
Supplementary Table S1. Blots were incubated for 2 h at
65C in pre-hybridization Church’s buffer (0.5M Na-
phosphate buffer containing 7% SDS and 100 mg/ml of
salmon sperm carrier DNA). The labeled probe was heat
denatured in boiling water for 5min and snap cooled on
e107 Nucleic Acids Research, 2013, Vol. 41, No. 10 PAGE 4 OF 15
 at Edinburgh U
niversity on July 15, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
ice. The probe was added to the hybridization buffer and
allowed to hybridize overnight at 65C. Blots were washed
twice for 30min at room temperature in 2 SSC, 0.1%
SDS and then three times for 30min at 65C in 0.1 SSC,
0.1% SDS. Blots were exposed to X-ray ﬁlm for 24 h
at 70C.
Chromatin immunoprecipitation assay and real-time PCR
Chromatin immunoprecipitation (ChIP) with antibodies
against trimethyl H3Lys4 (Upstate) and CENP-A was
carried out according to a previously described method
(29,36). Brieﬂy, cultured cells were cross-linked in 1%
formaldehyde for 10min at 37C. After addition of 1/10
volume of 1.25M glycine and incubation for 5min, ﬁxed
cells were washed twice with cold phosphate-buffered
saline. Soluble chromatin was prepared by sonication
(Bioruptor sonicator; Cosmo Bio) to an average DNA
size of 500 bp in sonication buffer and immnnopre-
cipitated in IP buffer (20mM Tris–HCl, pH 8.0, 600mM
NaCl, 1mM EDTA, 0.05% SDS, 1.0% Triton X-100,
20% glycerol, 1.5 mM aprotinin, 10 mM leupeptin, 1mM
DTT and 40 mM MG132). Protein G sepharose
(Amersham, USA) blocked with bovine serum albumin
was added, and the antibody–chromatin complex was re-
covered by centrifugation. The recovery ratio of the
immunoprecipitated DNA relative to input DNA was
measured by real-time PCR using a CFX96 real-time
PCR detection system (Bio-Rad, USA) and iQ SYBR
Green Supermix (Bio-Rad, USA). Primers for EYFP,
Bsr, Hygro, HS-tk transgenes, alphoidtetO repeat and
chromosome 21 alphoid repeat sequences, as well as for
control loci, 5S ribosomal DNA and pericentromeric sat-
ellite 2 repeats, are listed in Supplementary Table S1. At
least three independent ChIP experiments were performed
to estimate the level of enrichment.
Construction of BRV-tTS-EYFP retroﬁtting vector
The BRV-tTS-EYFP vector to retroﬁt transformation-
associated recombination (TAR)-isolated genes with a
loxP site and a gene-silencing cassette was constructed as
follows. First, the four following fragments with the ap-
propriate restriction sites at their ends were obtained by
PCR ampliﬁcation. The bovine globulin terminator (ter)-
cHS4-Amp-pBR322 fragment was PCR ampliﬁed from
plasmid pFB-tTS-EYFP (29) using speciﬁc primers B346
and B345 (Supplementary Table S1). This fragment was
digested with AsiSI and AscI. The cytomegalovirus
promoter-DsRed2 fragment was PCR ampliﬁed from plas-
mid pDsRed2-C1 (Clontech) using speciﬁc primers B350
and B349 (Supplementary Table S1). Before ligation, this
fragment was digested with BglII and AsiSI. The SV40pA
terminator sequence was PCR ampliﬁed from plasmid
phiC31 attP neo (41) using speciﬁc primers B348 and
B347 (Supplementary Table S1). Before ligation, this
fragment was digested with BamHI and SpeI. The
cHS4-CAG-tTS-YFP fragment was excised from the
plasmid pFB-tTS-EYFP (29) with endonucleases AvrII
and AscI. Each of the aforementioned fragments was
gel-puriﬁed, and the four fragments were assembled
together in a single ligation reaction. The intermediate
plasmid thus obtained was named 264-tTS-DsRed2.
That plasmid was checked by PCR, restriction digestion
and sequencing. Next, plasmids 264-tTS-DsRed2 and
BRV1 (42), modiﬁed by insertion of unique BsiWI site,
were digested with AvrII and AscI. The two fragments
were ligated together, producing the vector BRV-tTS-
EYFP. A detailed diagram of the BRV-tTS-EYFP
retroﬁtting vector is shown in Supplementary Figure S2.
The vector contains the 30-end of the HPRT gene, a loxP
gene acceptor sequence and two short targeting hooks
(<300 bp each) homologous to the TAR cloning vector
pVC604 used for gene isolation (42) separated by the
unique BsiWI site.
RESULTS
Chromatin changes in the alphoidtetO-HAC kinetochore
that may occur when a tTS cassette is expressed from
the HAC
To omit the necessity for viral vector transfection to
regulate the activity of the alphoidtetO kinetochore, we
investigated whether a single copy of a tTS-containing
cassette integrated into the HAC could induce inactivation
of the HAC kinetochore. We deduced that cells with a
single copy of tTS should have much lower level of the
chromatin modiﬁer than cells transfected under conditions
where potentially hundreds of vector molecules might
penetrate into the cell. More important, the presence of
the tTS cassette, with its multiple targets (thousands of
tetO sites) on the same DNA molecule (in cis conﬁgur-
ation) might produce a negative autoregulation of the ex-
pression of the tTS module itself. Indeed, such an in cis
conﬁguration for effector (tTS) and target (tetO) could
potentially generate a self-regulating repressive ﬂuctuating
heterochromatin-like system. This is because when the tTS
silencer reaches a certain level of saturation on alphoidtetO
array, the synthetic chromatin created will turn off its own
expression. Subsequently, when the level of the tTS
silencer falls, and then the tTS could potentially
re-emerge from its repressed state.
Based on these considerations, we have considered
several scenarios (Figure 1b and c). First, despite a rela-
tively low level of expression, the chromatin modiﬁer
might disrupt the CENP-A kinetochore domain and
induce HAC loss. Second, because of the self-induced sup-
pression of tTS expression (and as a result of this a rela-
tively low level of heterochromatinization of the
alphoidtetO array), the HAC kinetochore might escape
the inactivation seen in our previous studies (29),
perhaps because of the plasticity of human kinetochore
chromatin. However, because the HAC contains thou-
sands of tetO sites, induction of synthetic heterochroma-
tin-like repressed regions on the megabase-size alphoidtetO
array could potentially induce transcriptional silencing of
adjacent genes because of heterochromatin spreading. In
this case, the tTS module might provide a novel approach
to regulate the expression of HAC-encoded genes while
maintaining a functional HAC kinetochore.
In this study, several tTS-containing cassettes were
inserted into the alphoidtetO-HAC to determine the
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consequences of the silencer expression on HAC stability
and the expression of genes loaded onto the HAC.
Characterization of the gene-loading system in the
alphoidtetO-HAC propagated in human cells
The loxP site in the HAC was combined with the HPRT
sequence fragment such that gene-loading events could be
selected by reconstitution of the HPRT gene. All previous
experiments on gene loading into the alphoidtetO-HAC
were carried out in HPRT-deﬁcient CHO hamster cells
(35,37), as these are efﬁcient donors for HAC transfer
into different human cell lines. In this study, we performed
the gene loading directly in human cells.
For this purpose, the alphoidtetO-HAC containing a
single loxP gene-loading site was ﬁrst moved from CHO
cells into HPRT-deﬁcient HT1080 cells (43) via MMCT
under selection for Blasticidin (or BS) (Figure 2a). Eight
drug-resistant clones were isolated. The presence of the
MMCT MMCT
Human
HT1080
tetO-HAC
Chinese hamster
CHO
tetO-HAC
loxP
Chicken
DT40
MMCT
Human
HT1080
HPRT -
5’ HPRTloxP
loxP
EGFP HPRT
(a)
(b)
HT1080
HPRT -
HT1080
HPRT +
(c)
Fluorescence
FISH
EGPF expression
(d)
DAPI
Merge
X3.1-I-EGFP-I
3’ HPRT loxP
EGFP
Co-transfection
HAT 
selection
+
1 month
3 weeks
Cre
recombinase
Figure 2. Schematic diagram of a gene loading into the alphoidtetO-HAC propagated in human cells. (a) Three steps of MMCT to transfer the HAC
into HPRT-deﬁcient HT1080 cells. In chicken DT40 cells, a loxP gene-loading site was introduced into the HAC (35). This modiﬁed HAC was
transferred to hamster CHO cells and then to HPRT-deﬁcient human HT1080 cells. (b) Loading of the X3.1-I-EGFP-I construct into the HAC.
X3.1-I-EGFP-I contains a 30 HPRT sequence, loxP site and EGFP transgene. (c) FISH analysis of the HAC-containing HT1080 clones. The HAC
was visualized using a vector probe (red). Chromosomal DNA was counterstained with DAPI (blue). The HAC is indicated by an arrow.
(d) Fluorescence image of cells carrying the HAC with expressing X3.1-I-EGFP-I construct.
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autonomous form of the HAC was examined by FISH
analysis. This conﬁrmed that the HAC was maintained
autonomously in seven of the eight clones analyzed
(Figure 2c). Second, because the MMCT procedure can
lead to deletions and rearrangements of the alphoid DNA
array, four HAC-containing clones were checked for in-
tegrity by SpeI digestion and Southern-blot hybridization
as previously described (36). As seen, all clones have SpeI
proﬁles indistinguishable from the original alphoidtetO-
HAC generated in human cells (clone AB2.2.18.21)
(29,36) and from the HAC in CHO cells (Figure 3a).
A unique loxP site was previously inserted within a
mega-size alphoid DNA array of the alphoidtetO-HAC
(35). However, its position was not determined. For this
study, the location of the loxP site within the array was
mapped. Earlier we have shown that the entire 1.1-Mb
alphoid DNA array may be excised from the HAC by
PmeI digestion (36). For mapping, we used a previously
constructed alphoidtetO-HAC carrying the full-length
NBS1 gene sequence that contains a unique PmeI site
(in the NBS1 sequence) (37). Chromosome-size genomic
DNA of two independent NBS1-containing clones was
prepared in agarose plugs from human cells harboring
the alphoidtetO-HAC/NBS1, cut with PmeI endonuclease,
separated by CHEF gel electrophoresis and hybridized
with an alphoidtetO probe (Supplementary Table S1).
Southern-blot hybridization revealed two bands of 650
and 500 kb corresponding in sum to the continuous
1.1-Mb alphoid DNA array in the original HAC
(Figure 3b). Thus, the loxP site is located near the
middle of the alphoid DNA array of the alphoidtetO-
HAC. This means that genes loaded into the HAC loxP
site will be equally ﬂanked on either side by thousands of
tetO sequences.
To evaluate the efﬁciency of gene loading into the loxP
site of the alphoidtetO-HAC in human cells, a previously
constructed vector, 264-EGFP (or X3.1-I-EGFP-I), (Sup-
plementary Figure S1) and a Cre-recombinase expression
vector were co-transfected into cells carrying the HAC
(Figure 2b). Seven recombinant clones were selected by
growth on HAT medium after 12–15 days. PCR analysis
with speciﬁc primers (Supplementary Table S1) conﬁrmed
that the HPRT gene was reconstituted in all selected drug-
resistant clones (Figure 3c). Fluorescence microscopy
revealed expression of the EGFP transgene in all clones.
A ﬂuorescence image of one representative clone bearing
the HAC is shown in Figure 2d. The efﬁciency of gene
loading into the HAC in HPRT HT1080 cells was com-
parable with that observed in CHO cells (<1–2 104)
(35). In human cells, EGFP expression was stable for at
least 6 months under selective conditions (data not
shown). Thus, we conclude that genes of interest or trans-
gene constructs can be efﬁciently inserted into the
alphoidtetO-HAC propagated in human cells, and that
they are subsequently stably expressed.
One copy of tTS loaded into the alphoidtetO-HAC does
not inactivate the HAC kinetochore
To investigate the effects of a single copy of the tTS on the
mitotic stability of the HAC, three different transgene
cassettes were constructed (Figure 4a), and isogenic
human HT1080 cell lines containing the different con-
structs loaded into the alphoidtetO-HAC were generated.
Two cassettes contained the tTS and color markers, either
EYFP or DsRed2 (constructs #3 and #4). The tTS is fused
M2 1
1.1 Mb1120 + 1100
945 + 915
815
kb 
M1 1 2 3 4 5 6
97.0
kb 
48.5
23.1
9.4
(a)
(b) M2 1 2
1120+1100
945 + 915
815
745
680
610
555
450
375
295
225
650 kb
500 kb
kb 
785
(c) 1 2 43 5 6 7M
1.5
2.0
kb
Figure 3. Physical analysis of the alphoidtetO-HAC used for loading of
tTS-containing cassettes. (a) Analysis of integrity of the alphoidtetO-
HAC synthetic array after its transfer into HPRT-deﬁcient HT1080
cells. Genomic DNA from the cells with the HAC was digested
with SpeI endonuclease, separated by CHEF gel electrophoresis
(range 10–70 kb) and the transferred membrane was hybridized with
the tetO-alphoid probe. Lane 1: the HAC with the loxP site in
hamster CHO cells; lanes 2, 3, 4 and 5: four HAC clones with the
loxP site in HPRT-deﬁcient HT1080 cells; lane 6: the original HAC
(clone AB2.218.21) generated in human cells (29). M1- Pulse
MarkerTM 0.1–200 kb (Sigma-Aldrich). (b) Mapping of the loxP site
in a mega-base size alphoid DNA array. Genomic DNA from the
cells possessing the original HAC was digested with PmeI endonuclease,
separated by CHEF gel electrophoresis (range 200–1500 kb) and the
transferred membrane was hybridized with the tetO-alphoid probe. A
single 1.1-Mb fragment was detected for the original HAC (left, lane 1).
Two bands of 650 and 500 kb were detected for genomic DNA from
cells with the HAC bearing an inserted NBS1 gene (right, lanes 1 and
2). The size of the fragments was determined by comparison with the
DNA size standard, Saccharomyces cerevisiae chromosomes. Lane M2:
Yeast Chromosome PFG Marker BioLabs. (c) PCR analysis of clones
with insertion of X3.1-I-EGFP-I into the HAC conﬁrming restoration
of the full-length HPRT gene.
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to EYFP in construct #4. In construct #3, the DsRed2 and
tTS sequences are transcribed from the same promoter but
are separated by an internal ribosome entry site (IRES)
sequence(Supplementary Figure S1). A control cassette
containing the tetR that is co-expressed with DsRed2 via
an intervening IRES was also constructed (construct #2)
(Supplementary Figure S1). All cassettes encode a fusion
protein with a high afﬁnity for the multiple tetO sequences
in the alphoid array of the HAC. This binding to tetO
sequences is negatively regulated by doxycycline. The
loxP-targeted region in the HAC contains the drug-resist-
ance marker hygromycin (Hygro), the 50-end of the HPRT
gene and the thymidine kinase gene of herpes simplex
virus 1 (HS-tk) (35). After insertion of the transgene cas-
settes into the HAC and reconstitution of the HPRT gene,
the order and orientation of the genes is as shown in
Figure 4b. Importantly, this targeting site was not
ﬂanked by insulator elements. All cell lines were isolated
in the presence of doxycycline to prevent tTS binding with
the alphoidtetO array.
To evaluate the effect of a single copy of the tTS (either
fused to EYFP or co-expressed with DsRed2) on HAC
stability, cells bearing HACs carrying different constructs
were transferred into non-selective medium (HAT and
BS) either with doxycycline (dox+) to inhibit binding of
the tTS to the alphoidtetO array sequences or without
doxycycline (dox) to permit tTS binding. Cells were
maintained in these media for 7, 20 and 36 days, and
then FISH analysis was carried out with the probe
speciﬁc for the alphoidtetO-HAC. For each construct,
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Figure 4. Loading of tTS-containing cassettes into the alphoidtetO-HAC propagated in human cells. (a) Diagram of the transgene cassettes used in
this study. All cassettes contain a 30 HPRT sequence and loxP site. Control constructs are marked by either EGFP alone (construct #1) or DsRed2
that is co-transcribed with tetR (constructs #2). Experimental constructs contain the tTS (tetR with the KRAB-AB) either co-transcribed with DsRed2
(construct #3) or fused to EYFP (constructs #4). All constructs were inserted into the loxP site of the alphoidtetO-HAC propagated in HPRT-deﬁcient
HT1080 cells. (b) A map of the resulting transgene cluster in the HAC containing TK, Hygro and HPRT genes and a color marker. Arrows indicate
direction of transcription of the transgenes. (c) Mitotic stability of the HAC carrying different transgene cassettes after growing the cells in the
presence or absence of doxycycline. Two control clones containing the alphoidtetO-HAC in human HT1080 cells were checked for HAC loss after
transfection with a retroviral vector carrying the tTS. Two HAC-containing clones for each construct (#2, #3 and #4) were checked in human cells.
Two clones for construct #4 and one clone for construct #1 were also checked in CHO cells. Each clone was grown medium either with (open bars)
or without (black bars) doxycycline.
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two randomly chosen clones were analyzed, and for each
clone, at least 60 metaphases were examined. Figure 4c
shows the estimated rates of HAC loss (black bars corres-
pond to dox versus white bars correspond to dox+
medium). As expected, the absence or presence of doxy-
cycline had essentially no effect on stability of the HAC
lacking the KRAB-AB sequence (construct #2).
Expression of a tTS fusion protein from constructs #3
and #4 caused little, if any, increase in the population of
cells lacking the HAC when the cells were grown in the
absence of doxycycline compared with the HAC loss
induced by expression of tTS from a retrovirus vector.
Similar data were also obtained for hamster cells
carrying the tTS-containing HAC (Figure 4c). Altogether,
these data indicate that the expression of a single copy of
the tTS-containing cassette loaded into the alphoidtetO-
HAC does not induce signiﬁcant destabilization of
the HAC.
Expression of a single copy of tTS induces silencing of
transgenes in the alphoidtetO-HAC
In accordance with the prediction that the tTS could po-
tentially induce an autoregulated ﬂuctuating repressive
heterochromatin-like state on the alphoidtetO-HAC, we
observed a quick disappearance of the ﬂuorescence
signal expressed from the tTS-EYFP or tTS-DsRed2
cassette when the cells were grown in the absence of doxy-
cycline (Figure 5a and b). This silencing occurred in 93%
of cells after culturing for 7–10 days without the drug. A
similar phenomenon of transgene silencing in dox
medium without noticeable loss of the HAC was
observed in CHO cells (Figure 5c). Because in both cas-
settes, the sequence encoding a ﬂuorescent protein is either
fused or co-expressed with the tTS sequence, this obser-
vation reveals a progressive decrease in the tTS protein
under conditions when this protein binds to tetO
sequences.
To further characterize the autoregulation of tTS ex-
pression, the dynamics of tTS-EYFP expression (construct
#4) from the alphoidtetO -HAC in human cells were
analyzed in dox+ and dox media by measuring the
mean green ﬂuorescence (FACS) in the cell population.
Each measurement was the average of values for three
independent experiments. Figure 6a describes the
protocol for time-course analysis of tTS-EYFP protein
expression in the cells grown in different media. tTS-
EYFP transgene silencing was relatively stable because
even after 22 days of culture in dox medium, the tTS-
dox
removed
EYFP (+)
dox +
EYFP (-)
dox -
EYFP (+)
dox +
tetO-HAC
dox
added
dox+ dox- dox   returned+dox-
(a)
(c)
dox+ dox- dox-
EYFP EYFP EYFPLight microscope
DsRed2 DsRed2 Light microscope
7-10  days 6 days
(b)
Figure 5. (a) A schematic representation of the EYFP signal in the cells cultured in different media. (b) Fluorescence images of HT1080 cells with the
HAC carrying the tTS-EYFP cassette (construct #4) cultured in dox media and after adding doxycycline followed by 12 days of culture. Cells were
cultured without HAC selection (in HAT and BS medium). (c) Fluorescence images of CHO cells with the alphoidtetO-HAC carrying
the tTS-IRES-DsRed2 cassette (construct #3) cultured in dox+ and dox media. Cells were cultured without HAC selection (in HAT and
BS medium) for 30 days.
PAGE 9 OF 15 Nucleic Acids Research, 2013, Vol. 41, No. 10 e107
 at Edinburgh U
niversity on July 15, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
EYFP expression remained suppressed (Figure 6a and b;
sample 4). After growing for one additional month in
the presence of blastocidine (i.e. under selection for the
HAC), no recovery of transgene expression was
observed (Figure 6a and b; sample 5). At this point,
FISH analysis was carried out again, revealing the
presence of an autonomous alphoidtetO-HAC in 92% of
cells. Remarkably, this tTS-induced silencing of the EYFP
transgene was reversible. This was observed when the cells
with no detectable EYFP signal were transferred to
medium with doxycycline. After the cells were cultured
without selection for 24 h, the EYFP signal was partially
regained (Figure 6a and b; sample 7). The fraction of
cells expressing tTS-EYFP gradually increased after 6
and 12 days in dox+ culture (Figure 6a and b; samples 8
and 9).
We also examined whether other genes, Hygro, HS-tk
and HPRT, located in the same region of the HAC
(Figure 4b) were also silenced when the cells were
cultured in the absence of doxycycline. Using pairs of
primers speciﬁc to Hygro, HS-tk and HPRT genes (Sup-
plementary Table S1), RT–PCR analysis revealed bright
bands of the expected size (265, 267 and 449 bp, respect-
ively) in dox+medium (Figure 6c; lanes 4, 7 and 8). Either
no or faint bands (on the level of background) were
observed in dox medium (Figure 6c; lanes 3, 5 and 6).
As a control, expression of the genomic BRCA1 gene was
included. Using a pair of speciﬁc primers for exons 15–21
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Figure 6. Doxycycline regulated expression of the tTS-EYFP transgene loaded into the HAC. (a) A diagram illustrating time-course analysis of
tTS-EYFP expression in the cells grown in different media. Samples 1–11 correspond to cultures used for FACS analysis. The cultures marked by red
stars were analyzed by ChIP (see below). (b) Relative mean EYFP ﬂuorescence determined by FACS of cells carrying the tTS-EYFP cassette
(construct #4) grown in different media. Sample 1 corresponds to control HT1080 cells without the EYFP transgene (ﬂuorescence background).
Sample 2 corresponds to the cells with the HAC carrying the tTS-EYFP cassette grown in HAT and dox+medium for 30 days. Sample 3 corresponds
to the cells grown for 22 days in dox+medium without selection. Sample 4 corresponds to the cells grown for 22 days without doxycycline. Sample 5
corresponds to the cells grown for a month in dox medium with BS selection. Sample 6 corresponds to the cells grown in bsrdox medium.
Samples 7, 8 and 9 correspond to the cells grown in dox+BS+medium for 24 h, 6 and 12 days, correspondingly. Samples 10 and 11 correspond to the
cells treated either TSA or SAHA in dox+medium. Error bars, SD (n=3). (c) Transcription of Hygro, TK, EGFP and HPRT genes from the HAC.
The level of the transgene transcripts from cells cultured in dox+ or dox medium was analyzed by RT–PCR. The housekeeping gene, BRCA1, was
used as an internal control. Lane 1 (dox) and lane 2 (dox+) correspond to transcripts for BRCA1. Lane 3 (dox) and lane 4 (dox+) correspond to
transcripts for Hygro. Lane 5 (dox) and lane 7 (dox+) correspond to transcripts for TK. Lane 6 (dox) and lane 8 (dox+) correspond to transcripts
for HPRT. Lane 9 (dox) and lane 10 (dox+) correspond to transcripts for EGFP. Lane M- GeneRulerTM 1-kb DNA ladder. (d) ChIP analysis of
H3K4me3 chromatin in the transgene cassette of the HAC in the presence and absence of doxycycline. The cell samples used for ChIP correspond to
samples 2 and 6 in Figure 6a and b. Enrichment is shown relative to the 5S rRNA control locus. Satellite 2 sequence, Sat2, corresponding
endogenous pericentromeric repeats was included as a negative control. (e) ChIP analysis of CENP-A chromatin in the HAC in the presence and
absence of doxycycline. Enrichment is shown relative to the chromosome 21 centromere.
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of BRCA1 (Supplementary Table S1), almost equally
bright bands of 893 bp were detected in dox+ and dox
media (Figure 6c; lanes 1 and 2). As expected, for EGFP,
the faint and bright 483-bp bands were observed in dox
and dox+media, respectively (Figure 6c; lanes 9 and 10).
Thus, we concluded that binding of the tTS-EYFP to tetO
sequences silences genes located in regions neighboring the
loxP site of the alphoidtetO -HAC.
Based on known mechanisms of gene silencing induced
by the tTS (44,45), downregulation of the entire gene
cluster in the alphoidtetO-HAC is likely to be caused by
heterochromatinization of this region initiated from
nearby tetO sequences. Indirect support for this conclu-
sion came from experiments in which cells with silenced
transgenes were treated with the histone deacetylase in-
hibitors, TSA and SAHA (46). tTS-EYFP expression
was re-activated when these inhibitors were added to the
culture (Figure 6a and b; samples 10 and 11 compared
with sample 7), suggesting that an increase of the acetyl-
ation level of histone H3 in the HAC favors transcription
of the transgene.
Chromatin state of different regions of the
alphoidtetO-HAC in the presence and absence
of doxycycline
ChIP analysis was used to detect chromatin architecture
changes in the alphoidtetO-HAC DNA in the presence and
absence of tTS binding. Speciﬁcally, we analyzed the
chromatin structure of the HAC region containing the
tTS-EYFP, Hygro and HS-tk genes, as well as the Bsr
gene (repeated 30–40 times within the mega-size
alphoid DNA array). For this experiment, cells carrying
the HAC with construct #4 (tTS-EYFP) were grown either
in HAT and dox+or in dox medium (Figure 6a; samples
2 and 6). ChIP analysis revealed that H3K4me3, a marker
for active gene promoters, was associated with all three
transgene sequences when the cells were cultured in dox+
medium (Figure 6d). The level of H3K4me3 was higher at
tTS-EYFP than that at HS-tk and Hygro. This may be
due to the presence of two copies of the cHS4 insulator
upstream and downstream of tTS-EYFP. At the same
time, the level of H3K4me3 on the transgene sequences
dropped dramatically after removal of doxycycline
(Figure 6d), suggesting that the insulator sequences do
not protect expression of tTS-EYFP. A similar dynamic
was observed for the Bsr gene sequences scattered
throughout the megabase-size alphoid array. The Bsr
gene sequences were more enriched in H3K4me3 when
doxycycline was added into the medium compared with
when doxycycline was omitted. These results clearly
indicate that when tTS-EYFP cannot bind to alphoidtetO
repeats, the megabase-size synthetic array in the HAC
seems to form a more open chromatin structure. Thus,
based on these results, we hypothesize that when the
tTS-EYFP protein binds to tetO sequences after the
removal of doxycycline, the heterochromatin formed on
the alphoidtetO DNA array of the HAC spreads, leading to
transcriptional repression of transgenes located adjacent
to the gene-loading site. ChIP analysis also demonstrated
that tTS-induced silencing of the transgenes does not
affect the structure of centrochromatin in the HAC.
Speciﬁcally, no signiﬁcant difference in the level of
CENP-A was observed when cells were grown in the
presence or absence of doxycycline. Immunoprecipitation
with antibodies against CENP-A yielded an enrichment
for the alphoidtetO repeats in both cultures comparable
with that seen at the control endogenous centromere of
the chromosome 21 (Figure 6e). These results are in agree-
ment with mitotic stability of the HAC when the cells are
grown in the absence of doxycycline.
Development of an improved system to verify phenotypic
changes attributed to expression of HAC-encoded genes
The phenomenon of transgene silencing by a single copy
of the tTS can be used to develop a novel system to verify
phenotypes induced by genes inserted into the alphoidtetO-
HAC. This could be achieved by either modiﬁcation of the
original HAC vector (insertion of the tTS-containing
module) or loading of the chromatin modiﬁer cassette
into the HAC along with a gene of interest. In this
work, we exploited the second approach.
Previously the retroﬁtting vector pJBRV1 was con-
structed for loading full-length genes isolated by TAR
cloning (47–49) into the alphoidtetO-HAC (37). Here, we
have constructed a new retroﬁtting vector, BRV-tTS-
EYFP, that is applicable for the regulated expression of
TAR-isolated genes in the HAC (Figure 7a). The BRV-
tTS-EYFP vector contains a 30 HPRT-loxP cassette,
allowing gene loading into a unique loxP site of the
alphoidtetO-HAC, an independently expressed color
marker, DsRed2, that reports either the inhibition or ex-
pression of a gene of interest loaded onto the HAC, and a
single copy of the tTS fused to EYFP. In addition, similar
to pJBRV1, the new vector contains two targeting se-
quences (hooks) that have homology to the TAR vector
pVC604 used to clone full-length genes from complex
genomes (42,49). After target gene retroﬁtting and inser-
tion into the HAC, the tTS-EYFP fusion is constitutively
expressed from the HAC. In the presence of doxycycline,
the tTS-EYFP does not bind to the tetO sequences in the
alphoidtetO-HAC. Under these conditions, the HAC has
open chromatin permissive for expression of the DsRed2
color marker and a gene of interest. After doxycycline
removal, the tTS-EYFP fusion binds to tetO sequences
of the HAC, resulting in heterochromatin formation and
silencing of the two color markers and a target gene
(Figure 7b). As a proof of principle, the BRV-tTS-EYFP
vector was inserted into the loxP site of the alphoidtetO-
HAC in human HPRT-deﬁcient HT1080 cells, and expres-
sion of two color markers was analyzed. The predicted
loss of the ﬂuorescence signals of tTS-EYFP and
DsRed2 without detectable loss of the HAC was
observed in three of the three selected clones cultured in
the absence of doxycycline after 7–10 days (Supplemen-
tary Figure S3). Data for one representative clone are
shown in Figure 7c–e.
To summarize, gene loading into the alphoidtetO-HAC
using the BRV-tTS-EYFP vector allows us to control
gene expression from the HAC and thereby to verify
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Figure 7. Use of the retroﬁtting vector BRV-tTS-EYFP to regulate expression of a gene loaded into the HAC by doxycycline. (a) Diagram of the
retroﬁtting vector BRV-tTS-EYFP. The vector contains two targeting sequences (hooks) that are released by BsiWI endonuclease digestion. In vivo
recombination in yeast between the vector and a YAC containing the gene of interest (isolated by TAR cloning) leads to assembly of a circular
YAC/BAC molecule containing the gene of interest plus the tTS cassette all of which can be inserted into the HAC by Cre-lox recombination.
(b) Inactivation of a gene expression by modulating the epigenetic status of the underlying HAC kinetochore chromatin. The BRV-tTS-EYFP vector
along with a gene of interest is inserted into the single loxP site of the alphoidtetO-HAC. In the presence of doxycycline, the tTS cannot bind to tetO
sequences in the HAC, and this region of the HAC is transcriptionally active. Removal of doxycycline leads to tTS-induced heterochromatinization
of this region followed by gene silencing. (c) Fluorescence images of HT1080 cells with the HAC carrying the BRV-tTS-EYFP vector cultured in
dox+ and dox media followed by 10 days of culture without HAC selection (in HAT, BS medium). (d) Relative mean EYFP ﬂuorescence of cells
carrying the BRV-tTS-EYFP vector (FACS). (e) Mitotic stability of the HAC measured by FISH after growing the cells in the presence or absence of
doxycycline. Open bars correspond to the frequency of HAC loss when the cells were grown in the presence of doxycycline. Black bars correspond to
the frequency of HAC loss when doxycycline was excluded from the medium.
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gene-induced phenotypes without detectable HAC loss
from the cell.
DISCUSSION
The alphoidtetO-HAC carrying a megabase-size synthetic,
high-order alpha-satellite repeat array with a tetO in
every other alphoid monomer represents an advanced
HAC-based system for regulated gene delivery. The
main advantage of this HAC is that its kinetochore is
conditional and can be inactivated by tethering of the
tTS silencer or other repressive activities (29–32,35).
This feature provides a level of control for phenotypes
induced by a gene loaded into the HAC that is important
for gene function studies.
In our previous studies, induction of alphoidtetO-HAC
loss was initiated by transfection of cells by viral or
plasmid vectors expressing transcriptional repressors that
efﬁciently induce heterochromatin formation. This trans-
fection step is potentially mutagenic and might want to be
avoided under some circumstances. In the present study,
we demonstrated that the expression of a single copy of
the tTS-containing cassette from the HAC silences HAC-
encoded genes without inactivating the HAC kinetochore.
This process likely involves the formation of a limited
number of local heterochromatin domains as a conse-
quence of the presence of effector (tTS) and target sites
(tetO) on the same DNA molecule. Such a conﬁguration
generates a self-regulating ﬂuctuating repressive hetero-
chromatin-like state that is apparently not sufﬁciently
deep to inactivate the HAC kinetochore. However, the
level of heterochromatinization reached on the
alphoidtetO array is sufﬁcient to induce transcriptional
silencing of transgenes loaded onto the HAC. It is worth
noting that the observed phenomenon of gene silencing
seems to be caused by a unique combination of the
location of the gene-loading site (in the middle of a
megabase-size alphoid DNA array), and the positions of
tetO-recognition sites in the array that are accessible for
binding with the tTS silencer.
The presence of the color markers, DsRed2 and EYFP
(the second of which is present as a chimeric fusion to the
tTS suppresser itself), in the tTS-containing cassettes
allowed us to examine several parameters of heterochro-
matin seeding. Expression of the tTS-EYFP or DsRed2
protein was detectably suppressed after growing the cells
for 4–5 days without doxycycline (i.e. under conditions
when tTS-EYFP binds to tetO sequences in the HAC).
Taking into account that tTS-EYFP is a relatively stable
protein (50), this suggests that removal of doxycycline
results in relatively quick silencing of the tTS-EYFP tran-
scription. Such rapid gene silencing has been previously
reported for constructs with tetO-binding sites located im-
mediately upstream of a promoter sequence (44–45). In
our case, the nearest tetO sequences are 15 kb up and
15 kb down from the tTS-EYFP transgene and are
separated from tTS-EYFP by three other functional trans-
genes, HS-tk, Hygro and HPRT (Figure 4b). Indeed, most
of the tetO sequences are located hundreds of kilobases
away from the transgene. We found that the other
transgenes were also inactivated by tTS-induced
heterochromatinization initiated on the synthetic tetO-
alphoid DNA array. Importantly, inactivation of the
tTS-EYFP and other neighboring transgenes on the
HAC was reversed by the addition of doxycycline. Thus,
these observations indicate that tTS binding induces a re-
pressive heterochromatin-like state that can be converted
to transcriptionally permissive chromatin when tTS
binding is prevented. It should be noted that the
observed transgene silencing and its re-activation in the
HAC is in sharp contrast to previously described situ-
ations, where transgenes become silenced in cell lines
and transgenic animals (44,45). In all published works,
tTS was constitutively expressed, and transgenes regula-
tion was accomplished by the changing of afﬁnity of an
effector to a target. In our case, tTS regulates its own
expression and, as a consequence, the expression of neigh-
boring genes loaded onto the HAC.
Altogether, our ﬁndings demonstrate that expression of
a single autoregulated copy of the tTS from the
alphoidtetO-HAC provides an efﬁcient method to switch
off expression of the transgenes loaded onto the HAC,
thus allowing veriﬁcation of gene phenotypes by regulated
removal of the relevant gene product. The additional ad-
vantage of this system is the possibility to coordinately
silence groups of expressed genes, presumably because of
robust silencing spreading from the alphoidtetO array.
Another potential advantage of gene silencing in the
alphoidtetO-HAC carrying a single copy of tTS is that
the procedure does not lead to changes in the number of
chromosomes in the cell.
One advantage of HAC-based technologies is the op-
portunity to work with full-length genes. TAR cloning
allows selective isolation of any desired allele of a gene
of interest as a pre-determined chromosomal fragment in
yeast (47–49). The new retroﬁtting vector, BRV-tTS-
EYFP, described here links this gene isolation strategy
with the regulated gene expression in the alphoidtetO-
HAC. A hypothetical scheme illustrating the entire
process, including veriﬁcation of gene-induced pheno-
types, is diagrammed in Supplementary Figure S4.
In addition to gene expression experiments, the HAC-
based system described here may be useful for compara-
tive studies of chromatin barrier elements. The level of
protection of the tTS-EYFP transgene by ﬂanking se-
quences may be used to evaluate the activity of several
barrier elements. This approach is currently being used
to compare new barrier elements identiﬁed in our labora-
tory (39,40). Potentially, the phenomenon of tTS-EYFP
silencing may be also exploited to screen drugs affect-
ing de-condensation of heterochromatin. This is sup-
ported by our pilot experiments with inhibitors of
histone deacetylases, SAHA and TSA (manuscript in
preparation).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Table 1 and Supplementary Figures 1–4.
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